https://www.kpanews.co.kr/article/show.asp?idx=214433&category=D

D Pharmaceutical, a leading pharmaceutical company in Korea, challenged the patent of lipolysis injection (Belkaira formulation) of multinational pharmaceutical company A, and successfully invalidated Company A’s patent for a source of use. It was a very important case in that product authorization and sales could not be made if the original patent could not be invalidated while a claim for trial of the scope of rights was filed for subsequent patents. As a result of claiming the expanded source’s legal principles, AIP led to the invalidation of all important claims of the original patent, and it was an opportunity for D Pharmaceuticals to circumvent all of A's related patent networks.